Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • rondiamond510 rondiamond510 Jan 15, 2013 2:46 PM Flag

    Huge Catalysts Jan 18th DEA Coming. post.

    Seeking Alpha
    1/15/13 By: RX Stocks
    Arena's (ARNA) obesity drug, Belviq, was approved on June 27, 2012 and should receive final scheduling by the DEA soon. The DEA recommended Schedule 4 and is collecting comments through January 18, 2013, then a final decision should be forthwith. European approval may also be imminent (see Seeking Alpha), which could be a game changer. Vivus' (VVUS) drug Qsymia did not get European approval, which will give Belviq exclusivity in the European obesity market. The European sales potential for Belviq and a relatively weak start for Qsymia sales has lead to a change in my previous opinion, published by Seeking Alpha, for Arena's growth potential.

 
ARNA
1.68-0.03(-1.75%)Jul 28 4:00 PMEDT